Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787093 | 0.83 | CYP3A4 (0.48) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL282088 | 0.82 | CYP3A4 (0.52) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL31175763 | 0.81 | CYP3A4 (0.56) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL352023 | 0.81 | CYP3A4 (0.56) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL3784690 | 0.79 | CYP3A4 (0.45) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL14085077 | 0.79 | CYP3A4 (0.54) | CYP3A4TSHRCA1CA2EPHX2 | |
| SCHEMBL395438 | 0.78 | PRKCI (0.47) | CYP3A4TSHRALDH1A1CASP1RECQL | |
| SCHEMBL5491963 | 0.78 | CASP1 (0.50) | CYP3A4TSHRALDH1A1ALOX15THRB | |
| SCHEMBL29738343 | 0.78 | PRKCI (0.47) | CYP3A4TSHRALDH1A1CASP1RECQL | |
| SCHEMBL29414153 | 0.78 | CASP1 (0.50) | CYP3A4TSHRALDH1A1ALOX15THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023062627-A1 | HERBICIDES AND USE THEREOF | PROJINI AGCHEM LTD (IL) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021053234-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING KIDNEY DISEASE | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-03-25 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| EP-1173420-A2 | HETEROCYCLIC COMPOUNDS HAVING ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2002-01-23 | — | — | EP | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0051782-A1 | Process for the manufacture of m-halogenated anilines | BAYER AG (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0014344-B1 | COUMARIN COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS WHITENERS AND LASER DYES | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
| US-4326066-A | Triazolyl coumarin compounds, processes for their preparation and their use as whiteners and laser dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4324914-A | Process for preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-04-13 | — | — | US | disclosed |
| US-4233055-A | Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0014344-A1 | Coumarin compounds, process for their preparation and their use as whiteners and laser dyes | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| US-4193937-A | DECHLORINATION OF CHLOROANILINES, SELECTIVE HYDROGENATION CATALYSTS OF NOBLE METAL AND SULFUR | BAYER AKTIENGESELLSCHAFT (DE) | 1980-03-18 | — | — | US | disclosed |
| US-4141718-A | ANTIGROWTH AGENTS FOR PLANTS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4085141-A | Process for the preparation of anilines meta-substituted by chlorine | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-18 | — | — | US | disclosed |
| US-3947434-A | 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP3A4 177/4885TSHR 1688/4885CA1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.